Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYSCOVER
2016-001403-23Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of levodopa and carbidopa in Parkinson's disease (PD) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Change from baseline to week 12 in Unified Dyskinesia Rating Scale total score. Started Aug 2016; status: completed.
02
Drugs
levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2016-001403-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001403-23.